[Feature Stock] Remedy, strong on the first day of KOSDAQ listing... Up 30% from IPO price

Key takeaway

"[Feature Stock] Remedy, strong on the first day of KOSDAQ listing... Up 30% from IPO price" — BullBear's AI rates this story as a mixed, direction-neutral signal, with a market-impact score of 40 out of 100. Remedy is showing strength on its first day of KOSDAQ listing, rising significantly above its IPO price. It is currently trading 30.92% higher than its IPO price. That score reflects how strongly the story is likely to move Bitcoin, US equities, the dollar, and gold, and near-duplicate coverage of the same event is clustered so only the representative article is scored. BullBear analyzes hundreds of market stories a day this way, turning each into a structured bullish, bearish, or mixed read rather than a raw headline, so the signal can be compared across sources and over time. Reported by TokenPost on July 13, 2026. The bullish and bearish evidence behind this assessment, plus a 24-hour price-move check that verifies the call against what actually happened, are all tracked publicly on BullBear.news.